Research programme: lipid metabolism therapies - Catabasis Pharmaceuticals

Drug Profile

Research programme: lipid metabolism therapies - Catabasis Pharmaceuticals

Alternative Names: CAT 2000; CAT 3000

Latest Information Update: 17 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Eicosanoids; Nicotinic-acids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Cyclooxygenase inhibitors; Inflammation mediator inhibitors; Platelet aggregation inhibitors; Sterol regulatory element binding protein modulators; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Hypertriglyceridaemia

Most Recent Events

  • 17 Aug 2016 Research progrqamme still in preclinical development for Dyslipidaemia and Hypertriglyceridaemia in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertriglyceridaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top